Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Aurinia Pharmaceuticals Inc.

Filed: Jun 3, 2026CIK: 0001600620
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Aurinia Pharmaceuticals held its annual shareholder meeting on June 3, 2026, electing five board members with strong shareholder support ranging from 86.50% to 96.59%, signaling stable governance and investor confidence in the company's leadership direction.

Key Takeaways

Five board members elected: Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson, and Tina S. Nova, serving until the 2027 annual meeting

Kevin Tang received the highest shareholder support at 96.59% of votes in favor

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 3, 2026
Item5.02
CategoryExecutive Change
CIK0001600620
Accession #auph-20260603
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board changeleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings